The clinical data from NAFLD patients support the trends as predicted from the model, i.e., deregulated levels of HNF4α, HΝF1α, PPARγ, and SREBP-1c. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.